Biotechnology is fundamental to the continued growth and advancement of modern life. With cancer cases rising, the number of genetically occurring diseases increasing, and food production chains threatened by pests and disease, creating biologically engineered solutions to these issues is more crucial than ever.

Whether you refer to it as The Big C, a malignant neoplasm, or its simpler name; cancer, we all know what it is and have all heard and seen the detrimental effect it has on those fighting and living with it every day. With a devastating mortality rate and a plethora of heart-breaking films, podcasts, and charities to remind us why research is so fundamental, cancer is one disease we can’t seem to sweep under the rug. According to Stand Up to Cancer (SU2C) UK, one in two of us will get cancer in our lifetime which, as a harrowing statistic in itself, means that funding cancer research and the development of potential cures is vital.

Imagine being able to curate specific, complex collections of cells that directly resemble an individual patient's own tissues? Imagine no more... This technology has already been developed and is gaining steady traction across the market, alongside traditional ways of studying diseases outside of the body. Organoids, 3D cultures and laboratory animals have, and will continue, play a vital role in the way medicine works, as well as how doctors treat us as patients.

The genome-editing market offers a wealth of opportunity for the life science and healthcare industries. With the incidence of genetic disorders on the up, and growing applications in drug discovery and development, the market is being pushed into rapid growth. BCC Research’s latest report predicts the market will grow at a Compound Annual Growth Rate (CAGR) of 24.7% from 2022-2027. Given this hefty increase, we can expect to see significant advancements in disease treatments, helping drive the market further.

With the rising prevalence of life-threatening diseases and genetic disorders, the protein sequencing global market is set to increase in value for better diagnostic tools and biomarkers.

That global healthcare expenditure is on the rise is no secret. With longer life expectancies creating a higher geriatric population, an increased demand for high-performing medical technology has been witnessed across the board.
As such, the MedTech market is primed for serious growth. Companies must constantly reinvent product portfolios to gain leverage in the tricky landscape. With patient outcomes influencing technology pricing and purchase decisions, competition has become fierce and fast-paced.

Synthetic biology has established itself as a vital component of the life science industry in recent years. Combining principles of engineering with molecular biology, synthetic biology has achieved immense worldwide success. So much so, that by 2026, the market is expected to achieve a compound annual growth rate of more than 28% by 2026.

Globally, women’s health issues have gained significant traction in recent years. This is largely due to discrepancies in disease patterns – including illness, symptoms and response to illnesses – as well as the approach to the treatment of women’s illnesses within the healthcare system, in comparison to men’s healthcare.

In a recently published report, BCC Research examine the organ-on-a-chip market, which is expecting exponential growth over the forecast period 2021-2026:

The growing field of drug discovery and development is facilitating an environment of collaboration between researchers and the pharmaceutical industry. This allows researchers to focus on discovering essential lead compounds for different forms of cancer and other diseases.